HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

7-hydroxystaurosporine (UCN 01)

Subscribe to New Research on 7-hydroxystaurosporine

structure given in first source

Also Known As:

UCN 01; 7-hydroxy-staurosporine; UCN 02; UCN-01; UCN-02; 8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)triinden-1-one, 2,3,9,10,11,12-hexahydro-3-hydroxy-9-methoxy-8-methyl-10-(methylamino)-

Networked: 175 relevant articles (7 outcomes, 52 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 60

Experts

1.	Grant, Steven: 19 articles (05/2013 - 05/2002)
2.	Dent, Paul: 17 articles (05/2013 - 05/2002)
3.	Dai, Yun: 14 articles (05/2013 - 05/2002)
4.	Sausville, Edward A: 9 articles (10/2013 - 11/2002)
5.	Pei, Xin-Yan: 8 articles (02/2011 - 04/2004)
6.	Eastman, Alan: 7 articles (11/2009 - 07/2002)
7.	Rahmani, Mohamed: 6 articles (06/2005 - 07/2002)
8.	Dancey, Janet: 5 articles (01/2013 - 05/2007)
9.	Gandara, David R: 4 articles (04/2012 - 04/2003)
10.	Mack, Philip C: 4 articles (04/2012 - 04/2003)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2007 - "Thus, by defining the mechanism of cell death on G(2) checkpoint abrogation we show a highly improved strategy for an anticancer treatment by the combined use of UCN-01 with abrogators of the survivin/Aurora B-dependent antiapoptotic pathway that retains the selectivity for p53-defective cancer cells." 12/01/2015 - "The results of plasma profile and tumor regression study demonstrated that E-U-CH NP has continuous release profile of UCN 01 and comprehensive residence time. " 01/01/2007 - "Recent studies have reported that the PKC inhibitor, 7-hydroxystaurosporine, inhibits tumor cell invasion. " 02/01/2006 - "This phase I study was designed to determine the maximal tolerated dose (MTD), recommended phase 2 dose (RPTD), toxicity profile, pharmacokinetics and antitumor activity of T and UCN-01 in patients with refractory solid tumors. " 11/01/2005 - "The present studies determined whether UCN-01 and MEK1/2 inhibitors interacted to cause tumor cell death in vivo. "
2.	Breast Neoplasms (Breast Cancer) 01/01/2003 - "This combination may have potential clinical applications for breast cancer treatment, by reducing the toxicity of UCN-01." 07/19/2002 - "UCN-01 abrogated S and G(2) arrest in the p53 mutant breast tumor cell line MDA-MB-231 but not in the p53 wild-type breast line, MCF10a. " 01/01/2002 - "UCN-01 (7-hydroxystaurosporine) inhibits the growth of human breast cancer xenografts through disruption of signal transduction." 01/01/2013 - "A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer." 11/01/2005 - "In vitro colony formation studies demonstrated that UCN-01 and the MEK1/2 inhibitor PD184352 interacted to synergistically kill human mammary carcinoma cells (MDA-MB-231, MCF7) with similar combination index values. "
3.	Glioma (Gliomas) 06/01/1996 - "It is concluded that UCN-01 is an effective agent for the inhibition of glioma proliferation in vitro and in vivo and has potential for clinical applicability in the treatment of human gliomas." 04/01/2005 - "UCN-01 inhibits the invasion and migration of human glioma cells. " 06/01/1996 - "A striking inhibition of proliferation was produced by UCN-01 in each of the cell lines, with a median effective concentration of 20 to 100 nM, which correlated with the median in vitro PKC inhibitory concentration of 20 to 60 nM for this agent in the U-87 and SG-388 glioma cell lines. " 04/01/2005 - "Accordingly, UCN-01 can have potential clinical applications for the treatment of human glioma metastasis." 06/01/2002 - "These studies suggest that induction of apoptosis in glioma cells by use of UCN-01 may promote the uptake of tumor antigens by DCs. "
4.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/01/2004 - "To test the hypothesis that therapy-induced cell cycle effects would have an impact on the efficacy of a combination of UCN-01 plus ionizing radiation, the cell cycle responses of the non-small cell lung cancer cell lines Calu1 (TP53-null) and A549 (wild-type TP53) to 2 Gy ionizing radiation were correlated with clonogenic survival after irradiation plus UCN-01. " 09/01/1999 - "To determine whether specific genetic abnormalities would modulate the response to UCN-01, a model of human non-small cell lung carcinoma (NSCLC) cell lines with differential abnormalities of p16CDKN2, RB, and p53 was used for these studies. " 12/01/2004 - "Enhancement of radiation cytotoxicity by UCN-01 in non-small cell lung carcinoma cells." 09/01/1999 - "RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma." 09/01/1999 - "Long-term exposure of human A549 non-small cell lung cancer cells to UCN-01 furnished cells (A549/UCN) with acquired resistance against UCN-01. "
5.	Hematologic Neoplasms (Hematological Malignancy) 01/01/2001 - "In conclusion, flavopiridol and UCN-01 are cdk modulators that reach biologically active concentrations effective in modulating CDK in vitro, and show encouraging results in early clinical trials in patients with refractory hematopoietic malignancies. " 04/01/2002 - "Drugs showing activity with unique mechanisms of actions are being further developed for treatment of hematopoietic neoplasms, prominent examples being flavopiridol, UCN-01 and depsipeptide among others."

Related Drugs and Biologics

1.	Staurosporine
2.	Cisplatin (Platino)
3.	flavopiridol
4.	Topotecan (Hycamtin)
5.	Phosphotransferases (Kinase)
6.	Staphylococcal Protein A (A, Protein)
7.	Protein Kinase C
8.	Cyclins
9.	Protein Kinases (Protein Kinase)
10.	2- (2- chloro- 4- iodophenylamino)- N- cyclopropylmethoxy- 3,4- difluorobenzamide

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Heterologous Transplantation (Xenotransplantation)
3.	Parenteral Infusions
4.	Radiotherapy